Ischemia and No Obstructive Coronary Artery Disease
暂无分享,去创建一个
Christopher J. Rush | N. Sattar | C. Berry | R. Touyz | A. McConnachie | D. Collison | K. Oldroyd | S. Hood | S. Watkins | M. McEntegart | R. McGeoch | R. Good | T. Ford | D. Corcoran | N. Sidik | C. Rush | H. Eteiba | M. Lindsay | P. Rocchiccioli | A. Shaukat | K. Robertson | B. Stanley | P. McCartney | R. McDade | E. Yii
[1] C. Berry,et al. Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study , 2019, American heart journal.
[2] J. Kastrup,et al. Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction , 2019, International journal of cardiology. Heart & vasculature.
[3] Sean M. O'Brien,et al. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial , 2019, JAMA cardiology.
[4] Christopher J. Rush,et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. , 2018, Journal of the American College of Cardiology.
[5] B. Gersh,et al. Reappraisal of Ischemic Heart Disease: Fundamental Role of Coronary Microvascular Dysfunction in the Pathogenesis of Angina Pectoris , 2018, Circulation.
[6] R. Tavella,et al. Clinical and coronary haemodynamic determinants of recurrent chest pain in patients without obstructive coronary artery disease - A pilot study. , 2018, International journal of cardiology.
[7] N. Sattar,et al. Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial☆☆☆ , 2018, American heart journal.
[8] Akshay S. Desai,et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction , 2018, European heart journal.
[9] P. Barlis,et al. Physiological Predictors of Acute Coronary Syndromes: Emerging Insights From the Plaque to the Vulnerable Patient. , 2017, JACC. Cardiovascular interventions.
[10] W. Fearon,et al. Invasive Assessment of the Coronary Microvasculature: The Index of Microcirculatory Resistance , 2017, Circulation. Cardiovascular interventions.
[11] E. Prescott,et al. Sex-Related Differences in Vasomotor Function in Patients With Angina and Unobstructed Coronary Arteries. , 2017, Journal of the American College of Cardiology.
[12] C. Berry,et al. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need , 2017, Heart.
[13] S. Miyata,et al. 1057Important prognostic impact of comorbid coronary microvascular dysfunction in patients with vasospastic angina , 2017 .
[14] P. Libby,et al. Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade , 2017, Circulation.
[15] E. V. van Beek,et al. Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial , 2017, Heart.
[16] J. Kastrup,et al. Coronary Microvascular Function and Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive Coronary Artery Disease: The iPOWER Study , 2016, Journal of the American Heart Association.
[17] R Jay Widmer,et al. Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease. , 2015, JACC. Cardiovascular interventions.
[18] F. Crea,et al. International standardization of diagnostic criteria for vasospastic angina , 2015, European heart journal.
[19] O. Rimoldi,et al. Effects of Sex on Coronary Microvascular Dysfunction and Cardiac Outcomes , 2014, Circulation.
[20] Manesh R. Patel,et al. Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. , 2014, American heart journal.
[21] F. Crea,et al. Coronary microvascular dysfunction in patients without myocardial diseases and obstructive atherosclerosis , 2014 .
[22] J. Kaski,et al. Clinical Usefulness, Angiographic Characteristics, and Safety Evaluation of Intracoronary Acetylcholine Provocation Testing Among 921 Consecutive White Patients With Unobstructed Coronary Arteries , 2014, Circulation.
[23] Jeroen J. Bax,et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.
[24] Sankey V. Williams,et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.
[25] Sankey V. Williams,et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physi , 2012, Circulation.
[26] Carl J Pepine,et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. , 2010, Journal of the American College of Cardiology.
[27] Pamela S Douglas,et al. Low diagnostic yield of elective coronary angiography. , 2010, The New England journal of medicine.
[28] M. Woodward,et al. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC) , 2005, Heart.
[29] M. Delgado-Rodríguez,et al. Bias , 2004, Journal of Epidemiology and Community Health.
[30] A. Yeung,et al. Novel Index for Invasively Assessing the Coronary Microcirculation , 2003, Circulation.
[31] H. Fukuda,et al. Clinical and angiographical characteristics of acetylcholine- induced spasm: relationship to dose of intracoronary injection of acetylcholine , 2002, Coronary artery disease.
[32] F. N. van de Vosse,et al. Coronary Thermodilution to Assess Flow Reserve: Validation in Humans , 2002, Circulation.
[33] S. Higano,et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.
[34] C von Birgelen,et al. New signs characteristic of myocardial bridging demonstrated by intracoronary ultrasound and Doppler. , 1999, European heart journal.
[35] A Bol,et al. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. , 1994, Circulation.
[36] L. Melton,et al. Influence of referral bias on the apparent clinical spectrum of infective endocarditis. , 1990, The American journal of medicine.
[37] K. Okumura,et al. Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. , 1988, Journal of the American College of Cardiology.
[38] G. Rose,et al. Self-administration of a questionnaire on chest pain and intermittent claudication. , 1977, British journal of preventive & social medicine.
[39] Hiroaki Shimokawa,et al. International standardization of diagnostic criteria for microvascular angina. , 2018, International journal of cardiology.
[40] Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[41] B. Gersh,et al. ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology , 2013 .